Table 1.
Demographics and clinical and laboratory characteristics of COVID-19 and dengue patients (N = 93)
| COVID-19, N = 23 | Dengue, N = 70 | |
|---|---|---|
| Characteristics | n (%) | n (%) |
| Demographics | ||
| Median age (IQR)–yr | 45 (32–62) | 25 (17–42) |
| Male sex | 12 (52.17) | 34 (48.57) |
| Clinical | ||
| Mean length of symptoms before consultation (SD)–days | 6.04 (0.601) | 4.29 (0.214) |
| Median of oxygen saturation at admission (IQR)–% | 95 (89–98) | 98 (96–99) |
| Cough | 23 (100) | 3 (4.29) |
| Fever | 18 (78.26) | 69 (98.6) |
| Dyspnea | 14 (60.87) | 1 (1.43) |
| Myalgia | 10 (43.5) | 60 (85.7) |
| Diarrhea | 5 (21.7) | 19 (27.1) |
| Headache | 6 (26.1) | 49 (70) |
| Intense abdominal pain | 0 | 25/66 (37.9) |
| Arthralgia | 0 | 56 (80) |
| Nauseas | 3 (13.04) | 32 (45.7) |
| Rash | 0 | 22 (31.4) |
| Drop in hemoglobin (< 10 g/dL) | 2 (8.7) | 2 (2.9) |
| Respiratory support | 5 (21.74) | 1 (1.43) |
| Laboratory | ||
| Leukopenia (leukocytes < 3,500) | 0 | 26 (37.1) |
| Platelets < 150.000/uL | 2 (8.7) | 54 (77.1) |
| Platelets < 50.000/uL | 0 (0) | 21 (30) |
| AST > 2 times upper limit | 4/8 (50) | 41/62 (66.1) |
| AST > 3 times upper limit | 0 | 34/62 (54.8) |
| ALT > 2 times upper limit | 2/825 | 38/63 (60.3) |
| ALT > 3 times upper limit | 2/825 | 24/63 (38.1) |
| Serum creatinine elevation from baseline, N = 49 | 0 | 7/49 (14.3) |
ALT = alanine transaminase; AST = aspartate transaminase; IQR = interquartile range; SD = standard deviation.